Morningstar Investment Management LLC Trims Stock Holdings in Gilead Sciences, Inc. $GILD

Morningstar Investment Management LLC trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,570 shares of the biopharmaceutical company’s stock after selling 321 shares during the period. Morningstar Investment Management LLC’s holdings in Gilead Sciences were worth $1,394,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. One Wealth Advisors LLC grew its position in shares of Gilead Sciences by 34.8% during the 2nd quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock valued at $1,016,000 after purchasing an additional 2,364 shares in the last quarter. Ariel Investments LLC grew its position in shares of Gilead Sciences by 7.7% during the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock valued at $48,229,000 after purchasing an additional 30,630 shares in the last quarter. Golden State Wealth Management LLC grew its position in shares of Gilead Sciences by 14.5% during the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company’s stock valued at $97,000 after purchasing an additional 109 shares in the last quarter. Covea Finance grew its position in shares of Gilead Sciences by 69.5% during the 2nd quarter. Covea Finance now owns 51,700 shares of the biopharmaceutical company’s stock valued at $5,732,000 after purchasing an additional 21,200 shares in the last quarter. Finally, Swedbank AB grew its position in shares of Gilead Sciences by 0.8% during the 1st quarter. Swedbank AB now owns 2,118,632 shares of the biopharmaceutical company’s stock valued at $237,393,000 after purchasing an additional 16,663 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $118.21 on Tuesday. Gilead Sciences, Inc. has a 52-week low of $84.34 and a 52-week high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The company has a market capitalization of $146.68 billion, a P/E ratio of 23.55, a P/E/G ratio of 0.80 and a beta of 0.34. The company has a fifty day moving average of $114.72 and a 200-day moving average of $110.30.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm’s revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were paid a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.7%. Gilead Sciences’s payout ratio is currently 62.95%.

Analyst Ratings Changes

A number of research analysts have recently commented on GILD shares. Rothschild & Co Redburn boosted their price target on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research report on Friday, September 12th. JPMorgan Chase & Co. boosted their price target on shares of Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th. Truist Financial upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price target for the company from $108.00 to $127.00 in a research report on Friday, August 8th. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.08.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the sale, the chief financial officer directly owned 159,555 shares of the company’s stock, valued at $18,120,661.35. The trade was a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $340,710.00. Following the completion of the sale, the insider directly owned 113,193 shares of the company’s stock, valued at $12,855,329.01. This represents a 2.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 66,000 shares of company stock valued at $7,632,100 over the last three months. Insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.